VNDA logo

Vanda Pharmaceuticals (VNDA) Shareholders Equity

Annual Shareholders Equity

$544.91 M
+$17.71 M+3.36%

December 31, 2023

Summary

Performance

1-Year Change

+3.36%

3-Year Change

+20.22%

5-Year Change

+97.85%

15-Year Change

+314.74%

VNDA Shareholders Equity Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

83.2%
VNDA annual stockholders equity is higher than 83.2% of companies in Healthcare sector

High & Low

All-time High

$3.08 B
VNDA annual stockholders equity is currently -82.29% below its historical high of $3.08 billion

3-Year Low

$504.93 M
VNDA annual stockholders equity is currently +7.92% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
VNDA previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 7, 2025
VNDA next annual earnings announcement is scheduled for Feb 7, 2025

OtherVNDAbalance sheetmetrics:

Annual Retained Earnings

-$155.39 M
VNDA annual retained earnings is -$155.39 million

Annual Working Capital

$345.25 M
VNDA annual working capital is $345.25 million

Annual Total Assets

$648.44 M
VNDA annual total assets is $648.44 million

Annual Total Liabilities

$103.53 M
VNDA annual total liabilities is $103.53 million

Quarterly Shareholders Equity

$541.22 M
-$1.29 M-0.24%

September 30, 2024

Summary

Performance

3-Month Change

-0.24%

1-Year Change

-0.51%

3-Year Change

-0.51%

5-Year Change

-0.51%

VNDA Quarterly Shareholders Equity Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

82.69%
VNDA quarterly stockholders equity is higher than 82.69% of companies in Healthcare sector

High & Low

All-time High

$544.91 M
VNDA quarterly stockholders equity is currently -0.68% below its historical high of $544.91 million

3-Year Low

$502.12 M
VNDA quarterly stockholders equity is currently +7.79% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
VNDA previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 7, 2025
VNDA next earnings announcement is scheduled for Feb 7, 2025

OtherVNDAbalance sheetmetrics:

Quarterly Retained Earnings

-$169.38 M
VNDA quarterly retained earnings is -$169.38 million

Quarterly Working Capital

$343.30 M
VNDA quarterly working capital is $343.30 million

Quarterly Total Assets

$645.12 M
VNDA quarterly total assets is $645.12 million

Quarterly Total Liabilities

$103.89 M
VNDA quarterly total liabilities is $103.89 million

Shareholders Equity Formula

Shareholders Equity = Total Assets − Total Liabilities

Annual Shareholders Equity

$544.91 M
VNDA annual stockholders equity is $544.91 million

Annual Total Assets

$648.44 M
VNDA annual total assets is $648.44 million

Annual Total Liabilities

$103.53 M
VNDA annual total liabilities is $103.53 million

VNDA Shareholders Equity Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+3.4%-0.5%
3 y3 years+20.2%-0.5%
5 y5 years+97.8%-0.5%

VNDA Shareholders Equity Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+7.9%-0.7%+7.8%
5 y5-yearat high+32.6%-0.7%+31.7%
alltimeall time-82.3%+5401.4%-0.7%>+9999.0%

Vanda Pharmaceuticals Shareholders Equity History

DateAnnualQuarterly
Sep 2024
-
$541.22 M(-0.2%)
Jun 2024
-
$542.52 M(-0.3%)
Mar 2024
-
$544.00 M(-0.2%)
Dec 2023
$544.91 M(+3.4%)
$544.91 M(+0.3%)
Sep 2023
-
$543.10 M(+0.6%)
Jun 2023
-
$539.90 M(+0.8%)
Mar 2023
-
$535.74 M(+1.6%)
Dec 2022
$527.20 M(+4.4%)
$527.20 M(+2.2%)
Sep 2022
-
$515.66 M(+1.4%)
Jun 2022
-
$508.55 M(+1.3%)
Mar 2022
-
$502.12 M(-0.6%)
Dec 2021
$504.93 M(+11.4%)
$504.93 M(+2.4%)
Sep 2021
-
$493.32 M(+2.5%)
Jun 2021
-
$481.22 M(+2.9%)
Mar 2021
-
$467.63 M(+3.2%)
Dec 2020
$453.27 M(+10.3%)
$453.27 M(+2.9%)
Sep 2020
-
$440.57 M(+2.1%)
Jun 2020
-
$431.58 M(+3.6%)
Mar 2020
-
$416.39 M(+1.3%)
Dec 2019
$410.94 M(+49.2%)
$410.94 M(+2.5%)
Sep 2019
-
$400.91 M(+35.1%)
Jun 2019
-
$296.69 M(+6.6%)
Mar 2019
-
$278.40 M(+1.1%)
Dec 2018
$275.42 M(+109.6%)
$275.42 M(+5.4%)
Sep 2018
-
$261.42 M(+4.0%)
Jun 2018
-
$251.27 M(+4.2%)
Mar 2018
-
$241.14 M(+83.5%)
Dec 2017
$131.39 M(+0.0%)
$131.39 M(+0.7%)
Sep 2017
-
$130.47 M(-0.7%)
Jun 2017
-
$131.42 M(+2.6%)
Mar 2017
-
$128.14 M(-2.4%)
Dec 2016
$131.33 M(-1.3%)
$131.33 M(+1.7%)
Sep 2016
-
$129.16 M(+6.2%)
Jun 2016
-
$121.61 M(-1.1%)
Mar 2016
-
$123.01 M(-7.5%)
Dec 2015
$133.03 M(-17.3%)
$133.03 M(-8.8%)
Sep 2015
-
$145.94 M(-2.5%)
Jun 2015
-
$149.75 M(-1.8%)
Mar 2015
-
$152.47 M(-5.2%)
Dec 2014
$160.82 M(+264.5%)
$160.82 M(>+9900.0%)
Sep 2014
-
$1.06 M(+20.1%)
Jun 2014
-
$885.00 K(-95.8%)
Mar 2014
-
$20.98 M(-52.4%)
DateAnnualQuarterly
Dec 2013
$44.12 M(+345.5%)
$44.12 M(-11.8%)
Sep 2013
-
$50.00 M(+894.9%)
Jun 2013
-
$5.03 M(-22.5%)
Mar 2013
-
$6.48 M(-34.6%)
Dec 2012
$9.90 M(-70.4%)
$9.90 M(-35.5%)
Sep 2012
-
$15.35 M(-23.6%)
Jun 2012
-
$20.08 M(-25.4%)
Mar 2012
-
$26.92 M(-19.6%)
Dec 2011
$33.47 M(-11.3%)
$33.47 M(-11.2%)
Sep 2011
-
$37.68 M(-4.7%)
Jun 2011
-
$39.54 M(-0.1%)
Mar 2011
-
$39.57 M(+4.9%)
Dec 2010
$37.73 M(+63.8%)
$37.73 M(+10.5%)
Sep 2010
-
$34.16 M(+13.7%)
Jun 2010
-
$30.05 M(+12.8%)
Mar 2010
-
$26.63 M(+15.6%)
Dec 2009
$23.03 M(-50.0%)
$23.03 M(-21.7%)
Sep 2009
-
$29.41 M(-11.7%)
Jun 2009
-
$33.31 M(-20.4%)
Mar 2009
-
$41.84 M(-9.1%)
Dec 2008
$46.02 M(-45.0%)
$46.02 M(-12.5%)
Sep 2008
-
$52.59 M(-12.5%)
Jun 2008
-
$60.09 M(-13.7%)
Mar 2008
-
$69.66 M(-16.8%)
Dec 2007
$83.73 M(+212.9%)
$83.73 M(-15.7%)
Sep 2007
-
$99.29 M(-14.4%)
Jun 2007
-
$116.03 M(-8.5%)
Mar 2007
-
$126.81 M(+373.9%)
Dec 2006
$26.76 M(-12.7%)
$26.76 M(-27.6%)
Sep 2006
-
$36.95 M(-22.3%)
Jun 2006
-
$47.57 M(+238.3%)
Mar 2006
-
$14.06 M(-54.1%)
Dec 2005
$30.66 M(+92.3%)
$30.66 M
Dec 2004
$15.94 M(-99.5%)
-
Dec 2003
$3.08 B(+17.1%)
-
Dec 2002
$2.63 B(+2.2%)
-
Dec 2001
$2.57 B(+23.7%)
-
Dec 2000
$2.08 B(+1.1%)
-
Dec 1999
$2.06 B(+15.3%)
-
Dec 1998
$1.78 B(+35.7%)
-
Dec 1997
$1.31 B(+375.5%)
-
Dec 1996
$276.30 M(+42.2%)
-
Dec 1995
$194.30 M(+66.5%)
-
Dec 1994
$116.70 M
-

FAQ

  • What is Vanda Pharmaceuticals annual stockholders equity?
  • What is the all time high annual shareholders equity for Vanda Pharmaceuticals?
  • What is Vanda Pharmaceuticals annual shareholders equity year-on-year change?
  • What is Vanda Pharmaceuticals quarterly stockholders equity?
  • What is the all time high quarterly shareholders equity for Vanda Pharmaceuticals?
  • What is Vanda Pharmaceuticals quarterly shareholders equity year-on-year change?

What is Vanda Pharmaceuticals annual stockholders equity?

The current annual shareholders equity of VNDA is $544.91 M

What is the all time high annual shareholders equity for Vanda Pharmaceuticals?

Vanda Pharmaceuticals all-time high annual stockholders equity is $3.08 B

What is Vanda Pharmaceuticals annual shareholders equity year-on-year change?

Over the past year, VNDA annual stockholders equity has changed by +$17.71 M (+3.36%)

What is Vanda Pharmaceuticals quarterly stockholders equity?

The current quarterly shareholders equity of VNDA is $541.22 M

What is the all time high quarterly shareholders equity for Vanda Pharmaceuticals?

Vanda Pharmaceuticals all-time high quarterly stockholders equity is $544.91 M

What is Vanda Pharmaceuticals quarterly shareholders equity year-on-year change?

Over the past year, VNDA quarterly stockholders equity has changed by -$2.77 M (-0.51%)